The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,038.00
Bid: 12,036.00
Ask: 12,038.00
Change: -12.00 (-0.10%)
Spread: 2.00 (0.017%)
Open: 11,966.00
High: 12,072.00
Low: 11,966.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-UK says COVID-19 booster and annual vaccinations very probable

Sun, 07th Feb 2021 10:46

* Minister expects annual vaccinations may be needed

* Govt not planning vaccine passports -Nadhim Zahawi

* UK reports a further 15,845 cases, 373 deaths
(Adds latest figures, line on vaccine passports)

By Costas Pitas

LONDON, Feb 7 (Reuters) - A COVID-19 booster in the autumn
and then annual vaccinations are very probable, Britain's
vaccine deployment minister said on Sunday as countries race to
administer injections in the face of new variants.

Britain has already injected over 12 million first doses of
COVID-19 vaccines and is on track to meet a target to vaccinate
everyone in the top most vulnerable groups by mid-February.

Among coronavirus variants currently most concerning for
scientists and public health experts are the so-called British,
South African and Brazilian variants, which appear to spread
more swiftly than others.

"We see very much probably an annual or a booster in the
autumn and then an annual (vaccination), in the way we do with
flu vaccinations where you look at what variant of virus is
spreading around the world," Nadhim Zahawi told the BBC's Andrew
Marr Show.

AstraZeneca said on Saturday its vaccine developed
with the University of Oxford appeared to offer only limited
protection against mild disease caused by the South African
variant of COVID-19, based on early data from a trial.

Britain reported on Sunday a further 15,845 cases and 373
deaths within 28 days of a positive test, according to official
figures.

The success of the UK's vaccine rollout, however, is
spurring debate about how soon the government can ease broader
lockdown restrictions, amid plans to reopen schools in England
in March.

As some nations consider a vaccine passport to enable the
easing of travel measures, Zahawi said Britain would not
introduce such a system but people could seek proof from their
doctor if needed.

"That's not how we do things in the UK. We do them by
consent," he said. "We yet don't know what the impact of
vaccines on transmission is and it would be discriminatory."
(Reporting by Costas Pitas; Editing by Hugh Lawson and Susan
Fenton)

More News
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more
26 Feb 2024 07:22

AstraZeneca's blood-disorder drug recommended for EU approval

(Sharecast News) - European regulators has given the green light to AstraZeneca's blood-disorder drug Voydeya, the biopharma giant announced on Monday.

Read more
22 Feb 2024 17:36

EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and Thursday and not separately reported by Alliance News:

Read more
20 Feb 2024 10:29

AstraZeneca acquires US-based biopharmaceutical company

(Sharecast News) - Drugmaker AstraZeneca revealed late on Monday afternoon that it had successfully completed its acquisition of US-based biopharmaceutical company Icosavax.

Read more
20 Feb 2024 09:40

LONDON BROKER RATINGS: JPMorgan cuts Airtel Africa price target by 28%

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
19 Feb 2024 16:51

LONDON MARKET CLOSE: Europe lacks direction on quiet Monday

(Alliance News) - European markets lacked direction on Monday, after a quiet day as the US markets celebrated George Washington's birthday.

Read more
19 Feb 2024 15:59

London close: Stocks manage gains on globally quiet day

(Sharecast News) - London's financial markets finished in positive territory on Monday, with stocks closing in the green after overcoming minor losses earlier in the session.

Read more
19 Feb 2024 15:39

UPDATE: AstraZeneca completes USD1.1 billion acquisition of Icosavax

(Alliance News) - AstraZeneca PLC on Monday said it has completed the acquisition of Icosavax Inc.

Read more
19 Feb 2024 11:51

LONDON MARKET MIDDAY: Stocks lack direction amid quiet start to week

(Alliance News) - Stock prices in London lacked direction at midday Monday, amid a quiet start to the week.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.